Open AccessEstimating the Direct Medical Costs and Productivity Loss of Outpatient Chlamydia and Gonorrhea Treatment
Author(s) -
Sateesh Kumar,
Harrell W. Chesson,
Thomas L. Gift
Publication year - 2020
Publication title -
sexually transmitted diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.507
H-Index - 105
eISSN - 1537-4521
pISSN - 0148-5717
DOI - 10.1097/olq.0000000000001240
Subject(s) - gonorrhea , medicine , chlamydia , productivity , direct cost , medical care , indirect costs , medical costs , family medicine , health care , immunology , business , economic growth , accounting , human immunodeficiency virus (hiv) , economics
We used 2016-2017 administrative claims data to calculate the direct medical cost and productivity loss per diagnosed case of chlamydia and gonorrhea treatment. In 2018 US dollars, the direct cost per diagnosed case was $151 for chlamydia (n = 9180) and $85 for gonorrhea (n = 3048); productivity loss was $206 (n = 31) and $246 (n = 7), respectively, among those missing work seeking care.